Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
+ 1 more risk
Viatris Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.51 |
52 Week High | US$13.61 |
52 Week Low | US$8.77 |
Beta | 1.15 |
1 Month Change | -2.44% |
3 Month Change | -3.16% |
1 Year Change | 25.39% |
3 Year Change | -14.26% |
5 Year Change | n/a |
Change since IPO | -12.63% |
Recent News & Updates
Recent updates
Shareholder Returns
0A5V | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 0.9% | 6.3% | 1.1% |
1Y | 25.4% | 5.7% | 1.9% |
Return vs Industry: 0A5V exceeded the UK Pharmaceuticals industry which returned 5.4% over the past year.
Return vs Market: 0A5V exceeded the UK Market which returned 2.3% over the past year.
Price Volatility
0A5V volatility | |
---|---|
0A5V Average Weekly Movement | 4.2% |
Pharmaceuticals Industry Average Movement | 7.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.5% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A5V has not had significant price volatility in the past 3 months.
Volatility Over Time: 0A5V's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1961 | 38,000 | Scott Smith | www.viatris.com |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
Viatris Inc. Fundamentals Summary
0A5V fundamental statistics | |
---|---|
Market cap | US$13.74b |
Earnings (TTM) | US$54.70m |
Revenue (TTM) | US$15.43b |
252.5x
P/E Ratio0.9x
P/S RatioIs 0A5V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0A5V income statement (TTM) | |
---|---|
Revenue | US$15.43b |
Cost of Revenue | US$8.69b |
Gross Profit | US$6.73b |
Other Expenses | US$6.68b |
Earnings | US$54.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
Earnings per share (EPS) | 0.046 |
Gross Margin | 43.64% |
Net Profit Margin | 0.35% |
Debt/Equity Ratio | 88.5% |
How did 0A5V perform over the long term?
See historical performance and comparison